ALVO
Alvotech
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IS
$5.36
−0.42%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
36.2x
EV/EBITDA
−2260.1x
Market Cap
$1.91B
MomentumView details →
1D Return
−0.42%
YTD Return
+5.04%
RSI (14)
74.7
ValuationView details →
P/E (Fwd)
36.2x
EV/EBITDA
−2260.1x
Market Cap
$1.91B
RSI (14)
74.7
MomentumView details →
1D Return
−0.42%
YTD Return
+5.04%
SummaryUpdated Jun 1, 2026
Alvotech (NASDAQ:ALVO) is an Iceland-based biotechnology company founded in 2013 that specializes in developing and manufacturing biosimilar medicines. The company went public in June 2022 and has invested approximately $2 billion over more than a decade to build a vertically integrated biosimilar platform. Alvotech operates globally with commercial reach extending to over 90 countries and maintains its headquarters in Reykjavik, Iceland, with additional operations including recent acquisitions in Sweden.
Similar companies
Latest newsMore news →
Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for its proposed biosimilars AVT34 (durvalumab) and AVT87 (emicizumab) in the U.S. and selected Asian markets.14d agoAlvotech announced its financial results for the first half of 2026 and provided a business update on August 19, 2026.16d agoAlvotech announced that the FDA closed its inspection of its manufacturing facility in Reykjavik, Iceland, with a Voluntary Action Indicated classification.37d ago